Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Oct 2014

Huang Ming-Yii, Liu Hsueh-Chiao, Yen Li-Chen, Chang Jia-Yuan, Huang Jian-Jhang, Wang Jaw-Yuan, Lin Shiu-Ru

Abstract excerpt

The KRAS oncogene was among the first genetic alterations in colorectal cancer (CRC) to be discovered. Moreover, KRAS somatic mutations might be used for predicting the efficiency of anti-epidermal growth factor receptor therapeutic drugs. Because the KRAS mutations are similar in the primary CRC and/or the CRC metastasis, KRAS mutation testing can be performed on both specimen types. The purpose of this study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Fluorouracil

Share to Leucovorin

Share to Neoplasm Recurrence, Local

Share to Organoplatinum Compounds

Share to ras Proteins

Source

Identifiers

PMID: 24964961
DOI: 10.1007/s13277-014-2263-8

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip.PMID 24964961Read ↗

Combined KRAS and TP53 mutation in patients with colorectal cancer enhance chemoresistance to promote postoperative recurrence and metastasis.Semantic proximity Read ↗

Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.Semantic proximity Read ↗

Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.Semantic proximity Read ↗

KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer.Semantic proximity Read ↗

Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).Semantic proximity Read ↗

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.Semantic proximity Read ↗

Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samplesSemantic proximity Read ↗

Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan.Semantic proximity Read ↗

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.Semantic proximity Read ↗

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.